A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain

201159 citationsJournal Articlegold Open Access

Authors

Neil A. Hagen · Alberta Health Services

Bernard Lapointe · Ottawa Hospital

May Ong-Lam · BC Cancer Agency

Benoit Dubuc · Hôtel-Dieu de Montréal

David Walde · Sault Area Hospital

Bruno Gagnon · McGill University

Robin Love · University of British Columbia

Abstract

Long-term treatment with tetrodotoxin is associated with acceptable toxicity and, in a substantial minority of patients, resulted in a sustained analgesic effect. Further study of tetrodotoxin for moderate-to-severe cancer pain is warranted.

Topics & Keywords

Pain Management and Opioid Use Pain Mechanisms and Treatments Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Current Oncology

Volume 18, Issue 3, pp. 109-116

DOI: 10.3747/co.v18i3.732

Field-Weighted Citation Impact: 2.88